ALT
Altimmune, Inc. [ALT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALT Stock Summary
Top ALT Correlated Resources
ALT
Top 10 Correlated ETFs
ALT
Top 10 Correlated Stocks
ALT
In the News
ALT Financial details
Company Rating
-
Market Cap
566.45M
Income
-86.76M
Revenue
426K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.34
Forward P/E
-
PEG
7.94
P/S
2257
P/B
4.18
P/C
-
P/FCF
-11.24
Quick Ratio
12.24
Current Ratio
12.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.62
EPS next Y
-
EPS next Q
-
EPS this Y
-8.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.25%
Revenue last 5Y
-40.68%
Revenue Q/Q
-89.78%
EPS Q/Q
38.46%
-
-
-
-
SMA20
-23.87%
SMA50
-35.74%
SMA100
-47.41%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-45%
ROC
-0.55%
Gross Margin
61%
Oper. Margin
-30609%
Profit Margin
-27007%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.09-14.84
52W High
-65.79%
52W Low
+139.5%
RSI
47.73
Rel Volume
0.43
Avg Volume
5.18M
Volume
2.21M
Perf Week
13.24%
Perf Month
-14%
Perf Quarter
-29.25%
Perf Half Y
-30.58%
-
-
-
-
Beta
0.059
-
-
Volatility
0.18%, 0.68%
Prev Close
5.27%
Price
4.79
Change
8.62%
Company Profile
- Volume Average 5.18M
- Market Capitalization 566.45M
- Employee 59
- CEO Dr. Vipin K. Garg Ph.D.
- Headquarters Gaithersburg,MD,US
- IPO Date 2017-05-26
-
Website
https://altimmune.com 
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
